Corifollitropin Alfa PDE report and OEL report profile
Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
Binds and activates the FSH receptor on ovarian granulosa cells, promoting follicular growth and development. The carboxy-terminal peptide extension prolongs activity compared with conventional recombinant FSH.
Indications / reported uses
Controlled ovarian stimulation, in combination with a GnRH antagonist, for development of multiple follicles in women participating in an assisted-reproduction programme
EMA product information also includes selected adolescent males with hypogonadotropic hypogonadism in combination with hCG; verify the latest age wording and local label
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Corifollitropin Alfa PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Corifollitropin Alfa Permitted Daily Exposure (PDE) report (the Corifollitropin Alfa PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Corifollitropin Alfa Occupational Exposure Limit (OEL) report (the Corifollitropin Alfa OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.